News

Clinical Trials Arena22h
ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...
Clinical Trials Arena23h
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.